SCHEMBL13616481

SCHEMBL13616481

C/C=N/N1CCN(Cc2cc(-c3cccnc3)no2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.52
CYP2E1 P05181 2/20 0.52
CYP2C9 P11712 2/20 0.52
CYP2B6 P20813 2/20 0.52
CYP2C19 P33261 2/20 0.52
CA12 O43570 1/20 0.47
CA9 Q16790 1/20 0.47
KDM4E B2RXH2 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13616467 0.89 SMN1; SMN2 (0.47) CA12CA9SMN1; SMN2LMNACYP11B1
SCHEMBL13616483 0.87 HDAC3 (0.41) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19
SCHEMBL13616469 0.83 NOTUM (0.51) ALDH1A1LMNAHDAC3HDAC4HDAC1
SCHEMBL13616475 0.83 HDAC3 (0.43) KDM4ESMN1; SMN2ALDH1A1LMNAHDAC3
SCHEMBL4312189 0.82 CYP2A6 (0.61) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19
SCHEMBL13616471 0.82 DRD2 (0.46) SMN1; SMN2ALDH1A1HDAC3HDAC4HDAC1
SCHEMBL13616468 0.82 NOTUM (0.48) CYP2C9CYP2C19SMN1; SMN2ALDH1A1LMNA
SCHEMBL13616480 0.81 CA12 (0.44) CA12CA9KDM4EALDH1A1CYP11B1
SCHEMBL13616473 0.80 HDAC3 (0.39) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL13616477 0.80 MAPT (0.49) CYP2C9CA12CA9SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275594-A1 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS JANSSEN PHARMACEUTICA NV (BE) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275594-A1 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS RIF1, ABCC1, HDAC6 CYP2A6 1607/4885CYP2E1 612/4885CYP2C9 1790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.